Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug

Physicians lack an FDA-approved way to limit oral mucositis in head and neck cancer patients. EpicentRx wants to change that—and has shared a closer look at the phase 2 data that persuaded it to take the program deeper into the clinic.